Christian Dreger Joins PAREXEL as Senior Vice President, PAREXEL Access and PAREXEL Consulting
BOSTON, September 19, 2016— PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services organization, today announced the appointment of Christian Dreger, Ph.D., as Senior Vice President, PAREXEL Access and PAREXEL Consulting. Dr. Dreger will oversee the strategy and operational management for both businesses. He will also serve on PAREXEL's Business Review Committee, the Company's senior-most leadership team, and assist in developing and implementing PAREXEL's strategic objectives.
“Christian brings deep industry experience and expertise to PAREXEL. Throughout his career, he has held global, regional, and local positions in emerging and established markets and in various commercial functions and cross-functional roles with great successes,” said Josef von Rickenbach, Chairman and Chief Executive Officer, PAREXEL. “Christian’s leadership strengthens our ability to deliver best-in-class commercialization, market access and consulting services, helping our clients deliver innovative medicines and products to patients around the globe.”
Dr. Dreger joins PAREXEL from Biogen where he served as Vice President and Head of Global Commercial Operations, Biosimilars, in Zug, Switzerland. He has also held international commercial and sales positions of increasing responsibility with billion-dollar P&L and performance management responsibilities at Cubist Pharmaceuticals, AstraZeneca, Schering-Plough, and Roche Pharmaceuticals and Diagnostics. He started his career as a consultant with McKinsey & Co. in Germany.
“PAREXEL is recognized for its global expertise in consulting, regulatory outsourcing and market access services. I look forward to helping PAREXEL achieve our growth goals and further our mission,” said Dr. Dreger. “In particular, I am eager to work with our clients to support their consulting needs and to help insure that they meet their market access and reimbursement goals.”
Dr. Dreger holds an MBA and a Ph.D. from the University of Mannheim in Germany and St. Gallen, Switzerland, and an Executive MBA from Northwestern University's Kellogg Graduate School of Management. He also holds an LLB from the University of Hagen in Germany and is a certified pharmaceutical advisor and board director from INSEAD, Fontainebleau, France.
About PAREXEL International
PAREXEL International Corporation is a leading global biopharmaceutical services company, providing a broad range of expertise-based clinical research, consulting, medical communications, and technology solutions and services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, and reimbursement. PAREXEL Informatics provides advanced technology solutions, including medical imaging, to facilitate the clinical development process. Headquartered near Boston, Massachusetts, PAREXEL has offices in 84 locations in 51 countries around the world, and had approximately 18,600 employees in the fourth quarter. For more information about PAREXEL International visit www.PAREXEL.com.
PAREXEL and PAREXEL Informatics are trademarks or registered trademarks of PAREXEL International Corporation or its affiliates.
This release contains “forward-looking” statements regarding future results and events. For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words “believes,” “anticipates,” “plans,” “expects,” “intends,” “appears,” “estimates,” “projects,” “will,” “would,” “could,” “should,” “targets,” and similar expressions are also intended to identify forward-looking statements. The forward-looking statements in this release involve a number of risks and uncertainties. Such factors and others are discussed in the section entitled “Risk Factors” of the Company’s most recent Annual Report on Form 10-K and subsequent quarterly reports on Form 10-Q filed with the Securities and Exchange Commission, which “Risk Factors” discussion is incorporated by reference in this press release. The Company specifically disclaims any obligation to update these forward-looking statements in the future. These forward-looking statements should not be relied upon as representing the Company’s estimates or views as of any date subsequent to the date of this press release.
# # #